Silence Therapeutics (NASDAQ:SLN) Sees Strong Trading Volume – What’s Next?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) saw unusually-strong trading volume on Thursday. 733,544 shares were traded during trading, an increase of 19% from the previous session’s volume of 617,632 shares. The stock last traded at $9.1570 and had previously closed at $8.98.

Wall Street Analyst Weigh In

SLN has been the subject of a number of research reports. Morgan Stanley boosted their price target on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Cantor Fitzgerald started coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Silence Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $53.50.

Silence Therapeutics Price Performance

The business has a fifty day simple moving average of $12.48 and a two-hundred day simple moving average of $9.56. The company has a market cap of $547.00 million, a PE ratio of -7.10 and a beta of 1.45.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. On average, equities research analysts predict that Silence Therapeutics PLC Sponsored ADR will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Silence Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SLN. GAMMA Investing LLC raised its holdings in Silence Therapeutics by 18.1% in the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after purchasing an additional 1,698 shares in the last quarter. Seven Fleet Capital Management LP lifted its position in shares of Silence Therapeutics by 6.2% during the first quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after buying an additional 9,159 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of Silence Therapeutics during the second quarter valued at about $138,000. Squarepoint Ops LLC boosted its holdings in shares of Silence Therapeutics by 29.6% in the 2nd quarter. Squarepoint Ops LLC now owns 115,918 shares of the company’s stock valued at $1,273,000 after buying an additional 26,449 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Silence Therapeutics by 903.8% in the 1st quarter. Bank of America Corp DE now owns 29,773 shares of the company’s stock valued at $157,000 after buying an additional 26,807 shares in the last quarter. Institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company’s approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins.

Silence’s research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines.